CVRx (NASDAQ:CVRX) Posts Quarterly Earnings Results, Misses Expectations By $0.02 EPS

CVRx (NASDAQ:CVRX) posted its quarterly earnings data on Thursday. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.50) by ($0.02), FiscalAI reports. CVRx had a negative net margin of 84.93% and a negative return on equity of 152.35%. The company had revenue of $13.83 million for the quarter, compared to analysts’ expectations of $13.93 million.

Here are the key takeaways from CVRx’s conference call:

• CVRx lowered its 2026 revenue outlook to $56 million–$57 million from $58 million–$60 million, after Q3 revenue fell 6.1% year over year to $13.8 million. Q4 revenue is expected to be $11.7 million–$12.7 million.
• Reimbursement delays at UnitedHealthcare, CVRx’s largest Medicare Advantage payer, were a major drag: the 30-day approval rate for cases handled by the company fell to about 12% from a 2025 high of 83%. CVRx is appealing denials, but says the process can take months and many customer-handled denials may not be appealed.
• Physician-champion turnover and uneven sales-team experience are slowing adoption; four of nine U.S. regions are struggling to match the growth of the five more tenured regions. Management cited early improvement in team stability but said the recovery will take time.
• CVRx reported progress in coverage and clinical evidence: two written Medicare Advantage policies now cover a combined 21% of those lives, and traditional Medicare claims data showed all submitted Q1 2026 claims were paid. In the REBALANCE real-world study, the indicated-patient group had sustained functional-class improvements and improved ejection fraction through 24 months.
• CVRx ended Q3 with $58.7 million in cash and said it has at least 18 months of runway, excluding potential additional ATM proceeds. It expects 2026 operating expenses of $99 million–$101 million after cost reductions, while continuing to invest in sales and reimbursement.

CVRx Trading Down 7.0%

CVRx stock traded down $0.11 during trading hours on Thursday, reaching $1.47. The company had a trading volume of 274,601 shares, compared to its average volume of 516,611. The firm has a market cap of $39.16 million, a price-to-earnings ratio of -0.74 and a beta of 0.81. CVRx has a 12-month low of $1.25 and a 12-month high of $10.63. The company has a debt-to-equity ratio of 2.94, a current ratio of 8.04 and a quick ratio of 6.87. The company has a 50-day moving average price of $2.16 and a 200 day moving average price of $5.20.

Analysts Set New Price Targets

Several brokerages have issued reports on CVRX. Craig Hallum lowered CVRx from a “buy” rating to a “hold” rating and set a $4.00 price target for the company. in a research note on Friday, August 7th. Canaccord Genuity Group set a $5.00 target price on CVRx in a research report on Tuesday, September 22nd. Cantor Fitzgerald reduced their price target on shares of CVRx from $13.00 to $5.00 and set an “overweight” rating on the stock in a research report on Monday, August 17th. Lake Street Capital downgraded shares of CVRx from a “buy” rating to a “hold” rating and decreased their price target for the stock from $14.00 to $3.50 in a research note on Friday, August 7th. Finally, Wall Street Zen upgraded shares of CVRx from a “sell” rating to a “hold” rating in a report on Saturday, October 10th. Two investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $4.30.

Insider Buying and Selling

In other news, COO Brent Binkowski purchased 26,223 shares of the company’s stock in a transaction on Thursday, August 13th. The stock was acquired at an average price of $2.91 per share, with a total value of $76,308.93. Following the transaction, the chief operating officer directly owned 56,514 shares of the company’s stock, valued at approximately $164,455.74. This represents a 86.57% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 16.60% of the stock is owned by corporate insiders.

About CVRx

CVRx, Inc (NASDAQ: CVRX) is a medical device company focused on developing and commercializing neuromodulation therapies for patients with cardiovascular diseases. The company’s technology is designed to activate the body’s natural nervous system pathways to help regulate cardiovascular function.

CVRx’s primary product is the Barostim system, an implantable device that delivers electrical stimulation to baroreceptors located near the carotid arteries. By influencing signals between the cardiovascular system and the brain, Barostim is intended to reduce excessive sympathetic nervous system activity and improve symptoms and function in certain patients with heart failure.